Key Insights

Highlights

Success Rate

75% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 87/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

75.0%

-11.5% vs benchmark

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed with results

Key Signals

75% success

Data Visualizations

Phase Distribution

1Total

P 1 (1)

Trial Status

Completed3

Terminated1

Trial Success Rate

75.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (4)

Showing 4 of 4 trials

NCT04817449Completed

Spectroscopy in Ovarian Cancer

NCT05643599CompletedPrimary

The Relationship With Mad Honey Containing Grayanotoxin and Ovary Tissue

NCT05001282Phase 1Terminated

A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

NCT03897400Completed

Ovarian Reserve in Crohn's Disease

Showing all 4 trials

Ovary Disease